If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
207
results.
Updated on
18/05/2025 [06:53:00]
Results 100 to 125 of 207
Absstract of: CN119950757A
本发明针对肿瘤内过氧化氢不足和一氧化氮超短寿命的肿瘤治疗障碍，提出了一种活性氧和活性氮级联抗肿瘤纳米药物，以植物醛和天然氨基酸的联合作用作为抗肿瘤治疗的核心内容。以纳米颗粒为载体，在所述载体外包覆生物相容性材料，负载或接枝植物醛，封装天然氨基酸。在肿瘤酸性环境中，植物醛释放羟基自由基实现活性氧疗法。在产生羟基自由基的同时，植物醛还会缓慢释放过氧化氢，进而引发天然氨基酸向一氧化氮的转化，实现活性氮疗法。植物醛的控制释放致使一氧化氮释放得以可控，时空释放活性氧和一氧化氮的实现，从而充分利用活性氧和一氧化氮在药物动力学上的互补性，产生强大的抗肿瘤效应。本发明制备易操作，原料易获得，制备的负载植物醛和天然氨基酸的纳米颗粒具有较好颗粒分散性、化学稳定性和生物相容性，是一种理想的化学‑气疗‑铁死亡级联癌症治疗试剂。
Absstract of: CN119950538A
本发明提供了用于递送核酸药物的CXCR4抑制性聚合物及其应用。具体地，提供了一种活性成分组合在制备治疗肿瘤或抑制肿瘤细胞的药物组合物或药盒中的用途，其中，所述活性成分组合包括：(a)所述第一活性成分：靶向RRM2的核酸药物；和(b)第二活性成分：吉西他滨。本发明的含CXCR4抑制性聚合物的核酸药物纳米颗粒能够有效抑制胰腺癌的生长和转移。此外，本发明提供的核酸药物纳米颗粒与吉西他滨联用时，可协同地治疗胰腺癌，尤其是耐药性或难治性胰腺癌。
Absstract of: MX2021010150A
The present invention relates generally to the use of compositions including mesoporous silica particles that may be surface modified, for the delivery of viral vectors. In some embodiments, the viral vectors are used to transduce T cells to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
Absstract of: US2023331806A1
Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.
Absstract of: MX2022006821A
The present application relates to a formulation comprising at least one natural cannabis material, at least one solvent, and at least one stabilizer, wherein the formulation is a liquid suspension having a particle size (D<sub>90</sub>) of below 500 nm, and the use thereof in the treatment of a disease.
Absstract of: CN118634318A
The present invention relates to nucleic acid-containing lipid nanoparticles and uses thereof. Specifically, the present invention provides a lipid nanoparticle containing the following components (a) to (c): (a) a nucleic acid encoding a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR); (b) a cationic lipid; and (c) a non-cationic lipid. The invention also provides an immune cell expressing a CAR or expressing an exogenous TCR. The immune cell is produced by introducing the lipid nanoparticles into in vivo or in vitro T cells; and an in vivo or ex vivo therapeutic means for treating diseases including cancer using the immune cells.
Absstract of: WO2023205424A2
The present invention relates to ionizable lipids and lipid nanoparticle compositions thereof. The nanoparticle compositions are useful in the delivery of therapeutic agents such as nucleic acids.
Absstract of: CN119278031A
The present disclosure relates generally to the field of nucleic acid (e.g., DNA or RNA, in particular mRNA or inhibitory RNA, e.g., siRNA) compositions comprising a multivalent anion (e.g., inorganic polyphosphate), methods for preparing and storing such compositions, and use of such compositions in therapy.
Absstract of: CN119301261A
The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising a modified viral genome or self-replicating RNA, pharmaceutical compositions containing said nucleic acid molecules, and the use of such nucleic acid molecules and compositions for producing a desired product in a cell culture or in vivo. Also provided are methods for eliciting a pharmacodynamic effect in a subject in need thereof, as well as methods for preventing and/or treating a variety of health conditions.
Absstract of: CN119950450A
本发明公开了一种巨噬细胞膜包裹的纳米复合体、其制备方法及其应用，巨噬细胞膜包裹的纳米复合体是由巨噬细胞膜包裹且由表面阳离子特性的层状双氢氧化物LDH纳米材料和microRNA‑182制备得到的，纳米复合体的粒径为20~150 nm。本发明的巨噬细胞膜包裹的纳米复合体，一方面体内靶向心肌缺血再灌注损伤区域，另一方面对抗心肌缺血再灌注损伤后的心肌细胞焦亡，并且达到保护远期心功能改善心肌纤维化的目的，能够有效对抗心肌缺血再灌注损伤，对急性心肌梗死患者具有重大意义，应用前景好。
Absstract of: CN119950448A
本发明公开了一种γ‑聚谷氨酸/玉米醇溶蛋白复合纳米颗粒及其制备方法和应用，包括，将玉米醇溶蛋白溶于乙醇溶液中，得到玉米醇溶蛋白溶液；将γ‑聚谷氨酸溶于去离子水中，得到γ‑聚谷氨酸溶液；将玉米醇溶蛋白溶液加入γ‑聚谷氨酸溶液中，蒸发除去溶液中的乙醇，离心除去不溶物，得到γ‑聚谷氨酸/玉米醇溶蛋白复合纳米颗粒分散液；经冷冻干燥得到γ‑聚谷氨酸/玉米醇溶蛋白复合纳米颗粒粉末。本发明的γ‑聚谷氨酸/玉米醇溶蛋白复合纳米颗粒制备方法简单、成本低、且绿色安全，得到的纳米颗粒可以在较宽的pH、离子强度和温度范围内保持稳定，有着良好的生物相容性，可以应用于对生物活性成分的高效包埋，并改善其活性与稳定性。
Absstract of: CN119950699A
本发明公开了一种用于原位捕获抗原和淋巴结靶向递送的纳米疫苗及其制备方法和应用。该纳米疫苗包括聚合物纳米组装体和药物，所述聚合物纳米组装体包括两亲性聚合物与阳离子脂质体共组装体；所述两亲性聚合物包括聚乙二醇‑聚磷酸酯嵌段共聚物；所述药物包括免疫佐剂。本发明提供的纳米疫苗不仅可以用于原位捕获肿瘤抗原，还可以利用其小尺寸优势携带抗原和免疫激动剂靶向递送至肿瘤引流淋巴结，促进树突状细胞成熟，成熟树突状细胞加工处理抗原呈递给T细胞，激活CD8+T细胞，诱导强大的抗肿瘤免疫反应。
Absstract of: CN119950714A
本发明属于生物医药技术领域，具体涉及一种多模态成像的纳米诊疗剂及其制备方法和应用。该制备方法包括以下步骤：S1、配置IR780的二甲亚砜溶液；S2、配置单宁酸水溶液；S3、配置六水合三氯化铁水溶液；S4、超声状态下向IR780的二甲亚砜溶液中逐滴滴加超纯水，滴加完毕继续超声；S5、超声状态下向S4混合液中逐滴滴加单宁酸水溶液，滴加完毕继续超声；S6、超声状态下向S5混合液中逐滴滴加三氯化铁水溶液，滴加完毕继续超声，8000～10000转速离心水洗。本发明克服了传统诊断剂及治疗剂治疗周期长等不足，具有生物相容性好、毒副作用小和光调控能力强的优点。
Absstract of: JP2024056845A
To provide a therapeutic nanoparticle comprising an oncologic drug and taurolidine, which harness the synergistic effect of taurolidine on these oncologic drugs so as to allow for greater efficiency and reduced toxicity associated with the oncologic drugs.SOLUTION: Provided is a therapeutic nanoparticle, comprising at least one oncologic drug and taurolidine, whereby to provide the simultaneous delivery of the at least one oncologic drug and taurolidine, thereby harnessing the synergistic effect of taurolidine on the at least one oncologic drug. Preferably, the at least one oncologic drug comprises TNF-related apoptosis-inducing ligand (TRAIL).SELECTED DRAWING: None
Absstract of: CN119949514A
本发明提供一种具有减肥功效的纳米微胶囊及其制备方法和应用。该纳米微胶囊包括芯材和包覆在芯材表面的壁材，其中，芯材包括椰子甘油二酯，壁材包括食源肽、药食同源物质、表没食子儿茶素没食子酸酯。本发明的纳米微胶囊可以通过多种途径促进脂肪分解、以多机制的方式达到减肥功效，促使每个组分发挥协同效应，从而增强整体的减肥功效，且对人群具有普适性；其能够控制体重及腰围，调理脂代谢平衡，遏制食欲，从而达到减肥的功效，还具有缓解高脂饮食造成的肝脏、肾脏的炎性病变的潜力，最终达到健康减肥的功效。
Absstract of: AU2023276484A1
Provided herein are compounds comprising an oligonucleotide molecule conjugated to a ligand for a glucose transporter (GLUT) for modulation of a target molecule, compositions comprising the same, and methods of using the compositions.
Absstract of: CN119950396A
本发明属于生物医药技术领域，具体涉及一种含有肿瘤源性总RNA纳米疫苗的可溶性微针及其制备方法和应用。本发明利用鱼精蛋白可以和RNA以正负电相结合的特点，将鱼精蛋白、TdRNA和CpG复合，形成纳米疫苗，用于治疗或预防肿瘤。富含肿瘤抗原广谱遗传编码的TdRNA和CpG的协同作用随后驱动树突状细胞的成熟和细胞毒性T淋巴细胞的激活，从而产生强大的抗肿瘤免疫，有效地治疗或预防肿瘤，并且无显著的生理毒性，安全性高。此外，这种微针装载RNA疫苗的方式可以有效保护RNA，防止RNA体外降解，降低了储存及运输难度。
Absstract of: MY202341A
Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.
Absstract of: CN119950449A
本发明公开了一种用于猴痘预防的吸入式仿生纳米粒子及其制备方法与应用。所述吸入式仿生纳米粒子以模拟肺表面活性物质的脂质和巨噬细胞膜混合形成该纳米粒子的载体，包裹猴痘抗原和cGAMP，合成吸入式仿生纳米粒子，所述吸入式仿生纳米粒子可以有效增强抗猴痘病毒的体液免疫和细胞免疫。本发明还提供所述吸入式仿生纳米粒子在制备鼻吸入式疫苗制剂中的应用，所述鼻吸入式疫苗制剂能诱导在肺部和粘膜组织的粘膜免疫，有效地保护正痘病毒通过阴道和肠腔入侵，阻止猴痘病毒的性传播；以所述鼻吸入式疫苗免疫可以完全预防小鼠因正痘病毒属VACV的减毒株感染而死亡，且完全消除皮疹的产生，本发明对实现猴痘的有效预防具有意义。
Absstract of: CN119950733A
本发明属于药物载体技术领域，涉及一类可离子化脂质载体、其组合物与应用。该脂质载体为一种或多种氨基酸生育酚酯或其药学上可接受的盐，用于递送治疗剂或预防剂，其中，治疗剂或预防剂为siRNA、shRNA、miRNA及mRNA核酸分子，多肽或蛋白质中的一种或多种。在优选的实施例中，氨基酸结构部分为赖氨酸、组氨酸、精氨酸，或及其衍生物的残基。本发明还公开了包括一种或多种可离子化脂质载体与治疗剂或预防剂制成的组合物，以及该脂质载体或组合物在制备核酸药物、小分子药物、多肽或蛋白质药物中的应用，其中，所制备的负载RNA脂质纳米粒，可在体内表达或沉默蛋白，具有稳定性好、转染效率高、毒性低、安全有效等优点。
Absstract of: WO2025093665A1
The present disclosure relates generally to functionalized particles containing moieties capable of binding Immunoglobulin D (IgD), methods for producing them, and to pharmaceutical compositions containing them and their uses in medicine.
Absstract of: AU2023369585A1
The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.
Absstract of: WO2025091119A1
A blood cell-based therapeutic agent delivery system is disclosed. A blood cell-based therapeutic agent delivery vehicle is useful for delivering a therapeutic agent into a recipient organ cell. The blood cell-based therapeutic agent delivery vehicle is made by a method comprising encapsulating the therapeutic agent into a lipid nanoparticle to produce a therapeutic agent-containing lipid nanoparticle, and transfecting the therapeutic agent- containing lipid nanoparticle into a blood cell by incubating the therapeutic agent-containing lipid nanoparticle with the blood cell to form a transfected blood cell. The administration of the transfected blood cell causes the transfected blood cell to be in close proximity to or direct contact with the recipient organ cell, thereby causing a transfer of the therapeutic agent into the recipient organ cell. A composition for a blood cell-based therapeutic agent delivery vehicle for use in delivering a therapeutic agent into a recipient organ cell is also disclosed.
Absstract of: WO2025092866A1
Provided is an isolated mRNA molecule, which contains a nucleotide sequence encoding a chimeric immunogenic polypeptide, wherein the chimeric immunogenic polypeptide contains an immunogenic fragment of hemagglutinin (HA) of influenza A H5N1, an immunogenic fragment of hemagglutinin (HA) of influenza A H1N1, and an immunogenic fragment of hemagglutinin (HA) of influenza B Victoria, which are linked to each other. Further provided are a composition and vaccine containing the mRNA, a fusion protein encoded thereby, and a method using same for inducing an immune response to influenza virus in a subject.
Nº publicación: WO2025095526A1 08/05/2025
Applicant:
GREEN CROSS CORP [KR]
GREEN CROSS CORPORATION
Absstract of: WO2025095526A1
The present invention relates to a synthetic nucleic acid molecule comprising 3'-UTR polynucleotide with improved translation efficiency and a vaccine composition comprising the same, and more particularly to a synthetic nucleic acid molecule comprising 3'-UTR with improved translation efficiency manufactured by inclusion of specific motif and a codon-optimized signal sequence and an antigen encoding sequence, and a vaccine composition comprising the same. The synthetic nucleic acid molecule according to the present invention comprises a 3'-UTR polynucleotide with improved translation efficiency, which can effectively induce the expression of an antigenic polypeptide, which is useful for vaccine development because it can be expected to increase immunogenicity as a vaccine.
BOPI
Electronic site
